Study of 23ME-01473 in Patients With Advanced Solid Malignancies

Summary

This is a first-in-human open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-01473 given by intravenous infusion in participants with advanced solid cancers who have progressed or are intolerant of available standard therapies.

Timeline

Start

2024-03-07

Primary completion

2024-11-10

Completion

2024-11-10

Outcome

Outcome not reported

Stopped: “Sponsor cancelled study”

Drugs

Indications